Drug Effective In Slowing Progressive MS, Trial Shows

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study.

Patients treated with an IV infusion of ocrelizumab (Ocrevus) were less likely to have progression of their disability, researchers report in The Lancet.

Specifically, they had better hand function and arm dexterity, and they were less likely to need a wheelchair, researchers found.

“These findings are important because they show that treatment can make a meaningful difference to people with more advanced forms of MS and can help preserve hand and arm function, which is important for maintaining independence, daily activities and quality of life,” lead researcher Gavin Giovannoni said in a news release. He's a professor of neurology at Queen Mary University of London.

PPMS affects between 10% and 15% of people with multiple sclerosis, researchers said in background notes. Unlike relapsing forms of MS, disability worsens progressively over time, limiting treatment options.

There has been ongoing debate about whether people with more advanced MS might benefit at all from treatments like ocrelizumab, researchers said.

Ocrelizumab currently is prescribed to treat relapsing forms of multiple sclerosis, according to Drugs.com. It works by targeting and removing immune cells that promote MS-related inflammation.

For the new study, researchers recruited more than 1,000 PPMS patients across 22 countries, randomly assigning half to receive IV ocrelizumab every six months for nearly three years. The other half received a placebo IV, administered in the same way as the active drug.

Overall, patients treated with ocrelizumab had a 30% lower risk of disability progression, results showed.

Ocrelizumab also reduced the worsening of hand and upper-limb function by 41% at 12 weeks, and reduced the risk of requiring a wheelchair by 52%, researchers said.

Patients benefited even more if they had signs of inflammatory disease activity on baseline MRI scans, researchers said. There was a 55% lower risk of progression in those patients.

“MS can be debilitating, exhausting and unpredictable, and hand and arm function is essential for helping people to remain independent,” said Catherine Godbold, senior research communications manager at the MS Society in London.

“Many previous trials have focused solely on walking ability as a measure of whether a drug is effective. But trials like this are vital in helping us find treatments for everyone,” added Godbold, who reviewed the findings.

“Ocrelizumab is already used as a treatment for active relapsing MS and early primary progressive MS. These results could mean it is made available for more people with primary progressive MS, who don’t currently have access to any treatment options,” she said in a news release. “The key now is how we work together to see these findings translated into clinical practice."

Sources

  • Queen Mary University of London, news release, May 28, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-05-29 21:56

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords